Corindus Inc. Graduated from: TEIC Incubator Company Stage: R&D Established: 2002 Corindus is a global technology leader in robotic-assisted percutaneous coronary interventions. The company’s CorPath[R] 200 System offers interventional cardiologists complete PCI procedure control from an interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications. Technology Vascular Robotics. The proprietary technology utilizes physician fluoroscopic control similar to routine practice to allow maneuvering and torquing of cath lab devices. Initial clinical trials have demonstrated CorPath’s safety and efficacy. Unique to CorPath(TM) is the simplicity of integration into existing cath lab systems. Product Phase CorPath Clinical Trials 2012 - FDA clearance for the CorPath System Researcher: Prof. Rafael Beyarwww.corindus.com
Regentis Biomaterials Regentis Biomaterials is a tissue repair company that is developing and commercializing innovative biodegradable hydrogels for the local repair of damaged cartilage and bone. The platform technology is a family of hydrogels called Gelrin™. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage and bone.The Gelrin™ technology offers off-the-shelf products that aredesigned to be suitable for both open surgery and minimallyinvasive procedures. An ideal solution for physicians and theirpatients, the products are easy to implant and have been shownto stimulate the regeneration of healthy cartilage and bonetissue.http://www.regentis.co.il
Invision BiometricsFrom: Calcalist, Oct. 30, 2011:“Intel negotiates $50M acquisition of Invision BiometricsChip giant Intel aims to take Israels Invision onboard in bid to take on Microsofts; Invisioninvestors expected to gain 20 times their original inputInvision Biometrics, is a developer of 3D sensor PCBs which detect face and body movementand translate them into on-screen game moves.“http://www.ynetnews.com/articles/0,7340,L-4141247,00.htmlResearcher: Prof. Ron Kimmel
Azilect/Agilect (Rasagiline) An anti-Parkinsons disease drugDeveloped by Teva Pharmaceuticals in cooperation with Prof. Moussa Youdim andProf. John FinbergParkinson’s disease is a progressive condition that involves a gradual loss of nervecell function in the brain. The nerve cells that are specifically affected are thosethat control body movement~ 4 million people worldwide suffer from Parkinsons disease; it affectsapproximately 2-4% of the population over the age of 60, 1-2% in the generalpopulationAgilect®/Azilect®- Azilect® was launched in Israel in March 2005
Technology Transfer Issues How is it done at the Technion? Can we do it better? How lucrative is technology Transfer? Why do technology transfer?
Internal Sources for Advancement of IP Previously, about $600K per year Then, a “dry period” Currently, new funding is available The Kamin Program
AMITAlfred Mann Institute for Biomedical Development at the TechnionCurrently runs 4 projects: A biomimetic surgical tissue adhesive, entered Clinical Trials in October A innovative device for Glaucoma surgeries Stem Cells; suspension culture enabling platform for large scale expansion of human pluripotent stem cellsAn experimental drug: An anti-cancer compound, targeting cancer cells by a unique mechanism ~$25M over 2007-2012 $4.25 committed for 2013
AMIT Spinoff: SealantisBiomimetic adhesives for medical applications:The remarkable ability of algae to attach to wet solidSurface finding a material that will have similarcapabilities yet its commercial roduction will not rely onextracting natural materials.Compounds were mainly selected due to theirchemical similarity to the components of the naturalalgae glue.